Company news: FDA's "Stasi" scheme; Thermo Fisher Scientific and One Lambda; Forest Labs

Share this article:
Sen. Chuck Grassley unloaded on the FDA as a scandal over agency monitoring of dissident employee emails continued to unfold. Grassley said in a statement that the agency's actions against a staffer who corresponded with journalists and politicians about problems with the FDA's medical devices review process made it  “sound more like the East German Stasi than a consumer protection agency in a free country.” “What the FDA has done has serious implications for the right of federal employees to make valuable protected disclosures about waste, fraud, abuse, mismanagement, or public safety to Congress or anyone else.  This kind of communication is protected for good reason,” Grassley said. “The FDA's crusade contradicts the pledge the current commissioner made to create a culture that values whistleblowers, and the scope and tone of the surveillance effort reveals an agency more concerned about protecting itself than protecting the public, which ironically is the agency's mission.”

Thermo Fisher Scientific acquired diagnostics firm One Lambda, a California-based firm specializing in organ transplant diagnostics, for $925 million

Forest Labs reported Q1 2013 net sales down 31.9% to $751.8 million, from $1.1 billion in the year-ago period, with strong sales from Namenda, Bystolic and Savella and several products launching but failing to make up for the loss of Lexapro patent exclusivity. Sales of the SSRI were $110 million for the quarter – less than a fifth of what they were for the year-ago period.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.